Nigel James Temperton

The paper uses pseudotyped viruses and structural analysis to identify shared antigenic sites between influenza C and D viruses, suggesting potential for cross-protective vaccines.

This paper develops an ELISA-based pulldown method to isolate functional antigen-specific antibodies from serum samples, demonstrating high specificity and sensitivity for detecting neutralising antibodies against influenza haemagglutinin.

This study identifies HAT and swAT as proteases that activate ICV and IDV HEF proteins, showing that protease specificity does not restrict IDV replication in the human upper respiratory tract.

The paper reports high seroprevalence of SARS-CoV-2 in British deer, indicating potential reservoir capability and zoonotic risks from human-deer interactions.

This study identifies dipeptidase 1 as the receptor for PHEV, showing it does not require sialic acid and reveals structural versatility in receptor binding.

This paper introduces a dual neutralisation assay for SARS-CoV-2 and influenza viruses, demonstrating its sensitivity and specificity in detecting neutralising antibodies.

This paper demonstrates the immunogenicity and efficacy of a computationally designed DNA vaccine against H1N1 influenza in swine and mice, showing broad neutralizing antibody responses and reduced viral shedding.

This study investigates the factors driving the shift in dominance from H5N8 to H5N1 HPAIVs in wild birds, finding that viral pathogenicity and immune responses differ between subtypes.

The paper develops and optimizes pseudotyped viruses for influenza C and D to enable antiviral screening and sero-epidemiological studies.

The paper identifies monoclonal antibodies that neutralize multiple SARS-CoV-1, SARS-CoV-2 variants, and bat coronaviruses, with one antibody showing broad cross-reactivity.

This paper develops a vaccine candidate using DIOSvax-H5inter nanocages that elicits cross-clade neutralising antibodies and T cell responses against diverse H5 influenza strains.

This study shows sialoglycans promote endosomal, but not cell-surface, entry of SARS-CoV-2 and related sarbecoviruses.

The paper analyzes neutralizing antibodies from vaccinated and hybrid immune individuals to show that restored B cell germlines enhance neutralization against SARS-CoV-2 variants like BA.2.86.

This study develops a lentiviral pseudotype-based ELLA assay to assess antibody responses against influenza neuraminidase, showing it is sensitive and could replace traditional methods.